Canaccord weighs in on Edwards Lifesciences (EW +11.3%) after a stellar Q1 result, recommending...

|About: Edwards Lifesciences Corp (EW)|By:, SA News Editor

Canaccord weighs in on Edwards Lifesciences (EW +11.3%) after a stellar Q1 result, recommending investors buy the shares ahead of a few catalysts, including an NCD final decision expected in early May and a Cohort-A Panel in mid-June.